Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Minor: Revaccination With a Vaccine Called RSVpreF in Older Adults Trial sites expanded: 0 → 13 locations PfizerPhase 3 NCT07885956
  2. Minor: SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) Trial sites expanded: 7 → 13 locations Solid Biosciences Inc.Phase 3 NCT07160634
  3. Minor: IGNITE · Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Trial sites expanded: 42 → 50 locations Ono Pharmaceutical Co., Ltd.Phase 3 NCT07104032
  4. Minor: Symbiotic-GI-03 · PF-08634404 in Combination With Chemotherapy · Metastatic Colorectal Cancer Trial sites expanded: 372 → 401 locations PfizerPhase 3 NCT07222800
  5. Minor: Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy · Locally Advanced or Metastatic Non-Small Cell Lung Cancer Trial sites expanded: 484 → 560 locations PfizerPhase 3 NCT07222566
  6. Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 240 → 265 locations SanofiPhase 3 NCT07184996
  7. Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 461 → 481 locations SanofiPhase 3 NCT07184931
  8. Minor: Symbiotic-GI-16 · PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer Trial sites expanded: 100 → 124 locations PfizerPhase 2/3 NCT07392892
  9. Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations AbbViePhase 3 NCT07772492
  10. Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations AbbViePhase 3 NCT07880756
  11. Minor: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Trial sites expanded: 200 → 209 locations Olema Oncology, Inc.Phase 3 NCT07085767
  12. Minor: Intravenous Anifrolumab · Systemic Lupus Erythematosus in Pediatric Participants Trial sites expanded: 103 → 111 locations AstraZenecaPhase 3 NCT05835310
  13. Minor: Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Trial sites expanded: 93 → 97 locations PfizerPhase 3 NCT05156398
  14. Minor: Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder Trial sites reduced: 62 → 56 locations GRIN Therapeutics, Inc.Phase 3 NCT07224581
  15. Minor: Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Trial sites expanded: 1 → 11 locations CellCentric Ltd.Phase 3 NCT07772024
  16. Minor: Pegozafermin · MASH and Fibrosis (ENLIGHTEN-Fibrosis) Trial sites expanded: 370 → 375 locations Hoffmann-La RochePhase 3 NCT06318169
  17. Minor: Maintenance Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 109 → 152 locations SanofiPhase 3 NCT07184944
  18. Minor: Rimegepant in Adults When Used · Chronic Migraine Trial sites expanded: 19 → 38 locations PfizerPhase 3 NCT07729462
  19. Minor: Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Trial sites reduced: 136 → 133 locations UCB Biopharma SRLPhase 3 NCT05076617
  20. Minor: Momelotinib · Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Trial sites expanded: 0 → 3 locations GlaxoSmithKlinePhase 2/3 NCT07569081
  21. Minor: Oral Levosimendan Trial sites expanded: 9 → 14 locations Tenax Therapeutics, Inc.Phase 3 NCT07436689
  22. Minor: Pimicotinib · Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Trial sites expanded: 4 → 7 locations Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 2 NCT07499362
  23. Minor: Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial sites expanded: 3 → 9 locations AbbViePhase 2 NCT07744126
  24. Minor: VS-7375 · KRAS G12D-Mutated Non-Small Cell Lung Cancer Trial sites expanded: 24 → 27 locations Verastem, Inc.Phase 2 NCT07659782
  25. Minor: Symbiotic-GU-08 · PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies · Locally Advanced or Metastatic Renal Cell Cancer Trial sites expanded: 183 → 186 locations PfizerPhase 1/2 NCT07227415